Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients Harboring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression
Latest Information Update: 20 May 2024
At a glance
- Drugs HORA-PDE6B (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; First in man
- Sponsors Coave Therapeutics; eyeDNA Therapeutics
- 07 May 2024 According to a Coave Therapeutics Media Release, Phase I/II results will be discussed with US and European health authorities to define optimal path to making HORA-PDE6b available to patients with PDE6b Retinitis Pigmentosa.
- 07 May 2024 According to a Coave Therapeutics Media Release, data from this study were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 meeting in Seattle, WA, US.
- 07 May 2024 Results presented in a Coave Therapeutics Media Release.